|
|
(State or Other Jurisdiction of Incorporation)
|
(I.R.S. Employer Identification No.)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
||
Item 2.02
|
Results of Operations and Financial Condition
|
Item 8.01
|
Other Events
|
Item 9.01
|
Financial Statements and Exhibits
|
Exhibit No.
|
Description
|
|
99.1
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
NATIONAL INSTRUMENTS CORPORATION
|
||
By:
|
/s/ R. Eddie Dixon, Jr.
|
|
Name: R. Eddie Dixon, Jr.
Title: Chief Legal Officer, Senior Vice President & Secretary
|
• |
All-time record revenue of $421 million, up 14 percent year over year
|
• |
All-time record orders up 19 percent year over year
|
• |
Strong diluted GAAP EPS of $0.30
|
• |
All-time record diluted non-GAAP EPS of $0.60
|
• |
Cash and cash equivalents of $211 million as of December 31, 2021
|
• |
Returned $66 million to stockholders through stock repurchase and dividends
|
• |
All-time record revenue of $1.47 billion, up 14 percent year over year
|
• |
GAAP gross margin of 71 percent
|
• |
Non-GAAP gross margin of 75 percent
|
• |
Strong diluted GAAP EPS of $0.67
|
• |
Record diluted non-GAAP EPS of $1.68
|
• |
Returned $198 million to stockholders through stock repurchase and dividends
|
• |
GAAP revenue to be in the range of $385 million to $415 million, up 19 percent year over year at the midpoint
|
• |
GAAP diluted EPS to be in the range of $0.13 to $0.27, up 17 cents year over year at the midpoint
|
• |
Non-GAAP diluted EPS expected to be in the range of $0.35 to $0.49, up 31 percent year over year at the midpoint
|
National Instruments
|
||||||||
Condensed Consolidated Balance Sheets
|
||||||||
(in thousands)
|
||||||||
|
December 31,
|
December 31,
|
||||||
|
2021
|
2020
|
||||||
|
(unaudited)
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
211,106
|
$
|
260,232
|
||||
Short-term investments
|
—
|
59,923
|
||||||
Accounts receivable, net
|
341,275
|
266,869
|
||||||
Inventories, net
|
289,243
|
194,012
|
||||||
Prepaid expenses and other current assets
|
90,225
|
68,470
|
||||||
Total current assets
|
931,849
|
849,506
|
||||||
Property and equipment, net
|
253,668
|
254,399
|
||||||
Goodwill
|
583,589
|
467,547
|
||||||
Intangible assets, net
|
212,521
|
172,719
|
||||||
Operating lease right-of-use assets
|
58,641
|
67,674
|
||||||
Other long-term assets
|
74,717
|
72,643
|
||||||
Total assets
|
2,114,985
|
1,884,488
|
||||||
|
||||||||
LIABILITIES AND EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable and accrued liabilities
|
83,218
|
51,124
|
||||||
Accrued compensation
|
111,261
|
87,068
|
||||||
Deferred revenue
|
137,818
|
132,151
|
||||||
Operating lease liabilities
|
13,137
|
15,801
|
||||||
Other taxes payable
|
59,109
|
48,129
|
||||||
Debt - current
|
—
|
5,000
|
||||||
Other current liabilities
|
40,671
|
42,578
|
||||||
Total current liabilities
|
445,214
|
381,851
|
||||||
Debt - non-current
|
300,000
|
92,036
|
||||||
Deferred income taxes
|
14,249
|
25,288
|
||||||
Income tax payable - non-current
|
54,195
|
61,623
|
||||||
Deferred revenue - non-current
|
32,822
|
36,335
|
||||||
Operating lease liabilities - non-current
|
30,468
|
35,854
|
||||||
Other long-term liabilities
|
14,340
|
26,630
|
||||||
Total liabilities
|
891,288
|
659,617
|
||||||
|
||||||||
Stockholders' equity:
|
||||||||
Preferred stock
|
—
|
—
|
||||||
Common stock
|
1,323
|
1,312
|
||||||
Additional paid-in capital
|
1,129,647
|
1,033,284
|
||||||
Retained earnings
|
112,858
|
211,101
|
||||||
Accumulated other comprehensive loss
|
(20,131
|
)
|
(20,826
|
)
|
||||
Total stockholders' equity
|
1,223,697
|
1,224,871
|
||||||
Total liabilities and stockholders' equity
|
$
|
2,114,985
|
$
|
1,884,488
|
National Instruments
|
||||||||||||||||
Condensed Consolidated Statements of Income
|
||||||||||||||||
(in thousands, except per share data, unaudited)
|
||||||||||||||||
|
||||||||||||||||
|
Three Months Ended
|
Years Ended
|
||||||||||||||
|
December 31,
|
December 31,
|
||||||||||||||
|
2021
|
2020
|
2021
|
2020
|
||||||||||||
|
||||||||||||||||
Net sales:
|
||||||||||||||||
Product
|
$
|
377,303
|
$
|
327,714
|
$
|
1,304,609
|
$
|
1,137,603
|
||||||||
Software maintenance
|
43,338
|
40,124
|
165,072
|
149,068
|
||||||||||||
Total net sales
|
420,641
|
367,838
|
1,469,681
|
1,286,671
|
||||||||||||
|
||||||||||||||||
Cost of sales:
|
||||||||||||||||
Product
|
119,857
|
105,625
|
406,342
|
359,861
|
||||||||||||
Software maintenance
|
3,739
|
3,571
|
14,621
|
11,260
|
||||||||||||
Total cost of sales
|
123,596
|
109,196
|
420,963
|
371,121
|
||||||||||||
|
||||||||||||||||
Gross profit
|
297,045
|
258,642
|
1,048,718
|
915,550
|
||||||||||||
|
71%
|
|
70%
|
|
71%
|
|
71%
|
|
||||||||
Operating expenses:
|
||||||||||||||||
Sales and marketing
|
122,304
|
134,570
|
467,352
|
465,509
|
||||||||||||
Research and development
|
92,301
|
73,733
|
335,986
|
280,381
|
||||||||||||
General and administrative
|
32,543
|
36,883
|
127,215
|
129,863
|
||||||||||||
Total operating expenses
|
247,148
|
245,186
|
930,553
|
875,753
|
||||||||||||
Gain on sale of business
|
—
|
—
|
—
|
159,753
|
||||||||||||
Operating income
|
49,897
|
13,456
|
118,165
|
199,550
|
||||||||||||
Other income (expense)
|
(4,739
|
)
|
1,797
|
(14,590
|
)
|
(788
|
)
|
|||||||||
Income before income taxes
|
45,158
|
15,253
|
103,575
|
198,762
|
||||||||||||
Provision for income taxes
|
4,822
|
10,515
|
14,260
|
55,103
|
||||||||||||
Net income
|
$
|
40,336
|
$
|
4,738
|
$
|
89,315
|
$
|
143,659
|
||||||||
Basic earnings per share
|
$
|
0.31
|
$
|
0.04
|
$
|
0.68
|
$
|
1.10
|
||||||||
Diluted earnings per share
|
$
|
0.30
|
$
|
0.04
|
$
|
0.67
|
$
|
1.09
|
||||||||
|
||||||||||||||||
Weighted average shares outstanding -
|
||||||||||||||||
Basic
|
132,215
|
131,277
|
132,311
|
131,082
|
||||||||||||
Diluted
|
133,225
|
131,732
|
133,562
|
131,799
|
||||||||||||
|
||||||||||||||||
Dividends declared per share
|
$
|
0.27
|
$
|
0.26
|
$
|
1.08
|
$
|
1.04
|
National Instruments
|
||||||||
Condensed Consolidated Statements of Cash Flows
|
||||||||
(in thousands)
|
||||||||
Years Ended December 31,
|
||||||||
2021
|
2020
|
|||||||
(unaudited)
|
||||||||
Cash flow from operating activities:
|
||||||||
Net income
|
$
|
89,315
|
$
|
143,659
|
||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Depreciation and amortization
|
99,402
|
87,064
|
||||||
Stock-based compensation
|
74,583
|
58,376
|
||||||
Disposal gain on sale of business/asset
|
—
|
(159,753
|
)
|
|||||
Loss from equity-method investees
|
5,719
|
2,942
|
||||||
Deferred income taxes
|
(15,796
|
)
|
7,771
|
|||||
Net change in operating assets and liabilities
|
(110,020
|
)
|
40,708
|
|||||
Net cash provided by operating activities
|
143,203
|
180,767
|
||||||
Cash flow from investing activities:
|
||||||||
Acquisitions, net of cash received
|
(222,783
|
)
|
(334,981
|
)
|
||||
Proceeds from sale of assets/business, net of cash divested
|
—
|
160,266
|
||||||
Capital expenditures
|
(40,975
|
)
|
(49,652
|
)
|
||||
Capitalization of internally developed software
|
(1,464
|
)
|
(4,054
|
)
|
||||
Additions to other intangibles
|
(2,751
|
)
|
(1,441
|
)
|
||||
Acquisitions of equity-method and other investments
|
(15,753
|
)
|
(9,761
|
)
|
||||
Purchases of short-term investments
|
—
|
(206,330
|
)
|
|||||
Sales and maturities of short-term investments
|
60,297
|
384,652
|
||||||
Net cash used by investing activities
|
(223,429
|
)
|
(61,301
|
)
|
||||
Cash flow from financing activities:
|
||||||||
Proceeds from term loan
|
—
|
170,000
|
||||||
Payments of term loan
|
(98,750
|
)
|
(71,250
|
)
|
||||
Proceeds from revolving line of credit
|
300,000
|
20,000
|
||||||
Payments of revolving line of credit
|
—
|
(20,000
|
)
|
|||||
Debt issuance costs
|
(1,993
|
)
|
(1,893
|
)
|
||||
Proceeds from issuance of common stock
|
32,518
|
31,947
|
||||||
Repurchase of common stock
|
(55,000
|
)
|
(48,713
|
)
|
||||
Dividends paid
|
(143,113
|
)
|
(136,545
|
)
|
||||
Net cash provided by (used by) financing activities
|
33,662
|
(56,454
|
)
|
|||||
Impact of changes in exchange rates on cash
|
(2,562
|
)
|
2,604
|
|||||
Net change in cash and cash equivalents
|
(49,126
|
)
|
65,616
|
|||||
Cash and cash equivalents at beginning of period
|
260,232
|
194,616
|
||||||
Cash and cash equivalents at end of period
|
$
|
211,106
|
$
|
260,232
|
Three Months Ended
|
Years Ended
|
|||||||||||||||
December 31,
|
December 31,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
Stock-based compensation
|
||||||||||||||||
Cost of sales
|
$
|
1,092
|
$
|
979
|
$
|
4,580
|
$
|
3,766
|
||||||||
Sales and marketing
|
6,284
|
5,462
|
25,233
|
22,288
|
||||||||||||
Research and development
|
5,811
|
5,129
|
23,515
|
17,769
|
||||||||||||
General and administrative
|
5,335
|
4,251
|
21,384
|
14,552
|
||||||||||||
Provision for income taxes
|
(2,010
|
)
|
(445
|
)
|
(12,047
|
)
|
(8,705
|
)
|
||||||||
Total
|
$
|
16,512
|
$
|
15,376
|
$
|
62,665
|
$
|
49,670
|
||||||||
Amortization of acquisition-related intangibles and fair value adjustments
|
||||||||||||||||
Net sales
|
$
|
352
|
$
|
1,961
|
$
|
2,324
|
$
|
3,260
|
||||||||
Cost of sales
|
6,700
|
4,313
|
19,391
|
9,892
|
||||||||||||
Sales and marketing
|
3,334
|
1,965
|
10,192
|
5,264
|
||||||||||||
Research and development
|
320
|
9
|
320
|
94
|
||||||||||||
General and administrative
|
—
|
846
|
—
|
846
|
||||||||||||
Other expense (income)
|
531
|
124
|
2,007
|
487
|
||||||||||||
Provision for income taxes
|
(1,626
|
)
|
(606
|
)
|
(4,071
|
)
|
(2,554
|
)
|
||||||||
Total
|
$
|
9,611
|
$
|
8,612
|
$
|
30,163
|
$
|
17,289
|
||||||||
Acquisition-related transaction and integration costs, restructuring charges, and other(1)(2)
|
||||||||||||||||
Cost of sales
|
$
|
25
|
$
|
1,620
|
$
|
(25
|
)
|
$
|
1,626
|
|||||||
Sales and marketing
|
1,687
|
23,309
|
7,759
|
32,079
|
||||||||||||
Research and development
|
9,682
|
1,184
|
11,104
|
6,374
|
||||||||||||
General and administrative (1)
|
865
|
8,685
|
8,254
|
21,279
|
||||||||||||
Gain on sale of business/asset (2)
|
—
|
—
|
—
|
(159,753
|
)
|
|||||||||||
Other expense (income)
|
—
|
191
|
4,322
|
589
|
||||||||||||
Provision for income taxes
|
(2,708
|
)
|
(1,602
|
)
|
(6,837
|
)
|
32,364
|
|||||||||
Total
|
$
|
9,551
|
$
|
33,387
|
$
|
24,577
|
$
|
(65,442
|
)
|
|||||||
(1): During the third quarter of 2020, we recognized $5 million of compensation expense related to the replacement of unvested options
acquired from OptimalPlus. These amounts were accounted for as post-combination expense and will be recognized over the required service period
|
||||||||||||||||
(2): During the first quarter of 2020, we recognized a gain of $160 million related to the divestiture of AWR, presented within "Gain
on sale of business/assets".
|
||||||||||||||||
(Capitalization) and amortization of internally developed software costs
|
||||||||||||||||
Cost of sales
|
$
|
5,041
|
$
|
6,936
|
$
|
23,674
|
$
|
27,931
|
||||||||
Research and development
|
(188
|
)
|
(1,248
|
)
|
(1,433
|
)
|
(4,043
|
)
|
||||||||
Provision for income taxes
|
(1,085
|
)
|
(1,195
|
)
|
(4,877
|
)
|
(5,017
|
)
|
||||||||
Total
|
$
|
3,768
|
$
|
4,493
|
$
|
17,364
|
$
|
18,871
|
National Instruments
|
||||||||||||||||
Reconciliation of GAAP to Non-GAAP Measures
|
||||||||||||||||
(in thousands, unaudited)
|
||||||||||||||||
|
||||||||||||||||
Three Months Ended
|
Years Ended
|
|||||||||||||||
December 31,
|
December 31,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
Reconciliation of Net sales to Non-GAAP Net sales
|
||||||||||||||||
Net sales, as reported
|
$
|
420,641
|
$
|
367,838
|
$
|
1,469,681
|
$
|
1,286,671
|
||||||||
Impact of acquisition related fair value adjustments
|
352
|
1,961
|
2,324
|
3,260
|
||||||||||||
Non-GAAP net sales
|
$
|
420,993
|
$
|
369,799
|
$
|
1,472,005
|
$
|
1,289,931
|
||||||||
Reconciliation of Gross Profit to Non-GAAP Gross Profit
|
||||||||||||||||
Gross profit, as reported
|
$
|
297,045
|
$
|
258,642
|
$
|
1,048,718
|
$
|
915,550
|
||||||||
Stock-based compensation
|
1,092
|
979
|
4,580
|
3,766
|
||||||||||||
Amortization of acquisition-related intangibles and fair value adjustments
|
7,052
|
6,274
|
21,715
|
13,152
|
||||||||||||
Acquisition transaction and integration costs, restructuring charges and other
|
25
|
1,620
|
(25
|
)
|
1,626
|
|||||||||||
Amortization of internally developed software costs
|
5,041
|
6,936
|
23,674
|
27,931
|
||||||||||||
Non-GAAP gross profit
|
$
|
310,255
|
$
|
274,451
|
$
|
1,098,662
|
$
|
962,025
|
||||||||
Non-GAAP gross margin
|
74%
|
|
74%
|
|
75%
|
|
75%
|
|
||||||||
Reconciliation of Operating Expenses to Non-GAAP Operating Expenses
|
||||||||||||||||
Operating expenses, as reported
|
$
|
247,148
|
$
|
245,186
|
$
|
930,553
|
$
|
875,753
|
||||||||
Stock-based compensation
|
(17,430
|
)
|
(14,842
|
)
|
(70,132
|
)
|
(54,609
|
)
|
||||||||
Amortization of acquisition-related intangibles and fair value adjustments
|
(3,654
|
)
|
(2,820
|
)
|
(10,512
|
)
|
(6,204
|
)
|
||||||||
Acquisition transaction and integration costs, restructuring charges and other
|
(12,234
|
)
|
(33,178
|
)
|
(27,117
|
)
|
(59,732
|
)
|
||||||||
Capitalization of internally developed software costs
|
188
|
1,248
|
1,433
|
4,043
|
||||||||||||
Non-GAAP operating expenses
|
$
|
214,018
|
$
|
195,594
|
$
|
824,225
|
$
|
759,251
|
||||||||
Reconciliation of Operating Income to Non-GAAP Operating Income
|
||||||||||||||||
Operating income, as reported
|
$
|
49,897
|
$
|
13,456
|
$
|
118,165
|
$
|
199,550
|
||||||||
Stock-based compensation
|
18,522
|
15,821
|
74,712
|
58,375
|
||||||||||||
Amortization of acquisition-related intangibles and fair value adjustments
|
10,706
|
9,094
|
32,227
|
19,356
|
||||||||||||
Acquisition transaction and integration costs, restructuring charges and other
|
12,259
|
34,798
|
27,092
|
61,358
|
||||||||||||
Net amortization of internally developed software costs
|
4,853
|
5,688
|
22,241
|
23,888
|
||||||||||||
Gain on sale of business/assets
|
—
|
—
|
—
|
(159,753
|
)
|
|||||||||||
Non-GAAP operating income
|
$
|
96,237
|
$
|
78,857
|
$
|
274,437
|
$
|
202,774
|
||||||||
Non-GAAP operating margin
|
23%
|
|
21%
|
|
19%
|
|
16%
|
|
||||||||
Reconciliation of Provision for income taxes to Non-GAAP Provision for income taxes
|
||||||||||||||||
Provision for income taxes, as reported(1)
|
$
|
4,822
|
$
|
10,515
|
$
|
14,260
|
$
|
55,103
|
||||||||
Stock-based compensation
|
2,010
|
445
|
12,047
|
8,705
|
||||||||||||
Amortization of acquisition-related intangibles and fair value adjustments
|
1,626
|
606
|
4,071
|
2,554
|
||||||||||||
Acquisition transaction and integration costs, restructuring charges and other
|
2,708
|
1,328
|
6,837
|
4,122
|
||||||||||||
Net amortization of internally developed software costs
|
1,085
|
1,195
|
4,877
|
5,017
|
||||||||||||
Gain on sale of business/assets
|
—
|
274
|
—
|
(36,486
|
)
|
|||||||||||
Non-GAAP provision for income taxes(1)
|
$
|
12,251
|
$
|
14,363
|
$
|
42,092
|
$
|
39,015
|
||||||||
(1): The income tax effect related to each non-GAAP item is calculated based on the tax laws and statutory income tax rates
applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment, and considers the current and deferred tax impact of those adjustments.
|
Reconciliation of GAAP Net Income and Diluted EPS to Non-GAAP Net Income and Non-GAAP Diluted EPS
|
||||||||||||||||
(in thousands, except per share data, unaudited)
|
||||||||||||||||
|
||||||||||||||||
|
Three Months Ended
|
Years Ended
|
||||||||||||||
|
December 31,
|
December 31,
|
||||||||||||||
|
2021
|
2020
|
2021
|
2020
|
||||||||||||
|
||||||||||||||||
Net income, as reported
|
$
|
40,336
|
$
|
4,738
|
$
|
89,315
|
$
|
143,659
|
||||||||
Adjustments to reconcile net income to non-GAAP net income:
|
||||||||||||||||
Stock-based compensation
|
18,522
|
15,821
|
74,712
|
58,375
|
||||||||||||
Amortization of acquisition-related intangibles and fair value adjustments
|
11,237
|
9,218
|
34,234
|
19,843
|
||||||||||||
Acquisition transaction and integration costs, restructuring charges and other
|
12,259
|
34,989
|
31,414
|
61,947
|
||||||||||||
Net amortization of internally developed software costs
|
4,853
|
5,688
|
22,241
|
23,888
|
||||||||||||
Gain on sale of business/asset
|
—
|
—
|
—
|
(159,753
|
)
|
|||||||||||
Income tax effects and adjustments(1)
|
(7,429
|
)
|
(3,848
|
)
|
(27,832
|
)
|
16,088
|
|||||||||
Non-GAAP net income
|
$
|
79,778
|
$
|
66,606
|
$
|
224,084
|
$
|
164,047
|
||||||||
Non-GAAP net margin
|
18.9%
|
|
18.0%
|
|
15.2%
|
|
12.7%
|
|
||||||||
|
||||||||||||||||
Diluted EPS, as reported
|
$
|
0.30
|
$
|
0.04
|
$
|
0.67
|
$
|
1.09
|
||||||||
Adjustment to reconcile diluted EPS to non-GAAP diluted EPS
|
||||||||||||||||
Stock-based compensation
|
0.14
|
0.12
|
0.56
|
0.44
|
||||||||||||
Amortization of acquisition-related intangibles and fair value adjustments
|
0.09
|
0.07
|
0.26
|
0.15
|
||||||||||||
Acquisition transaction and integration costs, restructuring charges and other
|
0.09
|
0.27
|
0.23
|
0.47
|
||||||||||||
Net amortization of internally developed software costs
|
0.04
|
0.04
|
0.17
|
0.18
|
||||||||||||
Gain on sale of business/asset
|
—
|
—
|
—
|
(1.21
|
)
|
|||||||||||
Income tax effects and adjustments(1)
|
(0.06
|
)
|
(0.03
|
)
|
(0.21
|
)
|
0.12
|
|||||||||
Non-GAAP diluted EPS
|
$
|
0.60
|
$
|
0.51
|
$
|
1.68
|
$
|
1.24
|
||||||||
(1): The income tax effect related to each non-GAAP item is calculated based on the tax laws and statutory income tax rates applicable in the tax
jurisdiction(s) of the underlying non-GAAP adjustment, and considers the current and deferred tax impact of those adjustments.
|
||||||||||||||||
|
||||||||||||||||
Weighted average shares outstanding
|
||||||||||||||||
Basic
|
132,215
|
131,277
|
132,311
|
131,082
|
||||||||||||
Diluted
|
133,225
|
131,732
|
133,562
|
131,799
|
Reconciliation of GAAP to Non-GAAP Diluted EPS Guidance
|
||||||||
(unaudited)
|
||||||||
|
Three Months Ended
|
|||||||
|
March 31, 2022
|
|||||||
|
||||||||
|
Low
|
High
|
||||||
GAAP Diluted EPS, guidance
|
$
|
0.13
|
$
|
0.27
|
||||
Adjustment to reconcile diluted EPS to non-GAAP diluted EPS:
|
||||||||
Stock-based compensation
|
0.15
|
0.15
|
||||||
Amortization of acquisition-related intangibles and fair value adjustments
|
0.10
|
0.10
|
||||||
Acquisition transaction and integration costs, restructuring charges and other
|
0.01
|
0.01
|
||||||
Net amortization of internally developed software costs
|
0.01
|
0.01
|
||||||
Income tax effects and adjustments(1)
|
(0.05
|
)
|
(0.05
|
)
|
||||
Non-GAAP Diluted EPS, guidance
|
$
|
0.35
|
$
|
0.49
|
||||
(1): The income tax effect related to each non-GAAP item is calculated based on the tax laws and statutory income tax rates
applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment, and considers the current and deferred tax impact of those adjustments.
|